Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors.

[1]  Delong Liu,et al.  Second-generation inhibitors of Bruton tyrosine kinase , 2016, Journal of Hematology & Oncology.

[2]  M. Sawa,et al.  TR-FRET binding assay targeting unactivated form of Bruton's tyrosine kinase. , 2015, Bioorganic & medicinal chemistry letters.

[3]  M. Sawa,et al.  'Turn On/Off' fluorescence probe for the screening of unactivated Bruton's tyrosine kinase. , 2015, Bioorganic & medicinal chemistry letters.

[4]  S. Hymowitz,et al.  Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834. , 2015, Bioorganic & medicinal chemistry letters.

[5]  A. Kuglstatter,et al.  Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis. , 2015, Journal of medicinal chemistry.

[6]  M. Davids,et al.  Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. , 2014, Future oncology.

[7]  Laurens P. Kil,et al.  Targeting Bruton's tyrosine kinase in B cell malignancies , 2014, Nature Reviews Cancer.

[8]  Allard Kaptein,et al.  Irreversible protein kinase inhibitors: balancing the benefits and risks. , 2012, Journal of medicinal chemistry.

[9]  N. Horwood,et al.  Tec Family Kinases in Inflammation and Disease , 2012, International reviews of immunology.

[10]  W. Ellmeier,et al.  Tec family kinases: regulation of FcεRI‐mediated mast‐cell activation , 2011, The FEBS journal.

[11]  Brandon J. Bravo,et al.  Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. , 2011, Nature chemical biology.